EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Re‐Purposing Sapropterin (Kuvan) for ACTA2 ‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report

Moran Hausman-Kedem iD, Noa Bielopolski, Vijai Krishnan iD, Shane Wald-Altman, Shelly I Shrian, Omer Bar-Yosef, Livia Kapusta, Claire Shamber iD, Patricia L Musolino, Miguel Weil

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2375-2381

DOI: 10.1002/acn3.70493 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 26.07.2026. Verfasst von Moran Hausman-Kedem und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Actins, Cerebrovascular Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an ultra‐rare, ACTA2 ‐related disorder characterized by severe cerebrovascular disease, aortic aneurysms, and smooth muscle dysfunction. Using molecular dynamics simulations and in silico drug screening, we identified that sapropterin dihydrochloride (Kuvan) is a candidate capable of restoring p.R179H mutation disrupted actin polymerization. Patient‐derived fibroblasts demonstrated improved actin organization with Kuvan treatment. Off‐label treatment in a single pediatric patient with ACTA2 ‐MSMDS resulted in observed cerebrovascular stabilization and clinical improvement on longitudinal follow‐up. These findings provide first‐in‐human n‐of‐1 translational evidence supporting sapropterin as a potential disease‐modifying therapy for ACTA2 ‐related vasculopathies, while gene‐directed therapies are awaited. Further studies are needed to establish a robust therapeutic effect and to elucidate the mechanisms underlying the observed cerebrovascular benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ActinsCerebrovascular DisordersHumans

Stichwörter der Autor:innen

ACTA2cerebrovascular diseasepediatric strokesapropterinsmooth muscle dysfunction

Substanzen

ACTA2 protein, humanActins

Autor:innen und Institutionen

  • Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Gray Faculty of Medical and Health Science, Tel-Aviv University, Tel-Aviv, Israel.
  • QR Genetics, Tel Aviv, Israel.
  • Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Radiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Pediatric Neurology Unit, Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Moran Hausman-Kedem, Vijai Krishnan, Claire Shamber

Zitieren

APA

Hausman-Kedem, M., Bielopolski, N., Krishnan, V., Wald-Altman, S., Shrian, S. I., Bar-Yosef, O., Kapusta, L., Shamber, C., Musolino, P. L., & Weil, M. (2026). Re‐Purposing Sapropterin (Kuvan) for ACTA2 ‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report. Annals of Clinical and Translational Neurology, 13(11), 2375-2381. https://doi.org/10.1002/acn3.70493

Vancouver

Hausman-Kedem M, Bielopolski N, Krishnan V, Wald-Altman S, Shrian SI, Bar-Yosef O, et al. Re‐Purposing Sapropterin (Kuvan) for ACTA2 ‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report. Annals of Clinical and Translational Neurology. 2026;13(11):2375-2381. doi:10.1002/acn3.70493

BibTeX
@article{HausmanKedem2026,
  author = {Hausman-Kedem, Moran and Bielopolski, Noa and Krishnan, Vijai and Wald-Altman, Shane and Shrian, Shelly I and Bar-Yosef, Omer and Kapusta, Livia and Shamber, Claire and Musolino, Patricia L and Weil, Miguel},
  title = {Re‐Purposing Sapropterin (Kuvan) for ACTA2 ‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {2375--2381},
  doi = {10.1002/acn3.70493}
}
Kostenlos starten →